Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat

The effects of corticotrophin releasing factor (CRF) and handling stress on behavior in the elevated plus-maze test of anxiety

The effects on rodent anxiety of corticotrophin releasing factor (CRF), common experimental stressors and the CRF receptor blocker, α-helical CRF, were measured using the hole board and elevated plus-maze tests. Centrally administered (intracerebroventricular, i.c.v.) CRF increased anxiety in an anxioselective manner. α-Helical CRF (i.c.v) antagonized the effects of CRF, implicating central CRF receptors. Common experimental stressors, such as surgical implantation of cannulas and intraperitoneal injections of saline also selectively increased anxiety in the plus maze. Endogenous CRF binding to central CRF receptors probably mediates the anxiogenic effects of stressors, since α-helical CRF reversed the increased anxiety following surgery. Finally, repeated gentle handling seemed to blunt the anxiogenic effect of CRF. Handling also altered the effect of CRF on behavior, creating an apparently CRF-mediated suppression of rearing and exploration which was not present in rats not stressed with repeated handling. Together the data suggest a modifiable modulatory role of CRF in rodent anxiety. The findings also suggest that careful attention should be paid to stress history when examining the role of CRF in rodent behavior.

CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat

The role of the neuropeptide corticotropin-releasing factor (CRF) in mediating the behavioral effects of ethanol withdrawal in the rat was examined using the elevated plus-maze test. In Experiment 1, CRF (0.5 microgram ICV) reduced the percentage of time spent on the open arms of the elevated plus-maze, consistent with an "anxiogenic-like" effect. CRF also reduced the total number of arm entries, indicating a reduction in general activity. Low doses (5 and 25 micrograms ICV) of the CRF antagonist, alpha-helical CRF produced no behavioral effects in the elevated plus-maze, while a higher dose (50 micrograms ICV) elicited CRF-like activity. In experiment 2, rats were maintained for 2-3 weeks on a liquid diet containing ethanol (8.5-11.5% v/v) or sucrose. Eight hours after withdrawal from the ethanol diet rats displayed "anxiogenic-like" responses as well as a reduction in general activity in the elevated plus-maze compared with rats withdrawn from control diet. Alpha-helical CRF significantly antagonized the "anxiogenic-like" effects of ethanol withdrawal in the plus-maze. General activity and physical signs of ethanol withdrawal such as tail stiffness, body tremor and ventromedial distal flexion were unaffected by alpha-helical CRF. Blood Alcohol Levels (BALs) determined immediately after removal of the ethanol diet showed no group differences in ethanol consumption. These results suggest that increased activity of central CRF systems may mediate the anxiogenic effects of ethanol withdrawal.

Effects of 5-HT-1A receptor agonists on CRF-induced behavior

Buspirone (2.0 or 4.0 mg/kg) and 8-hydroxy-2-(di-N-propylamino)-tetralin (8-OH-DPAT) (0.25 or 0.5 mg/kg) were used to examine the effects of serotonin 1A receptor agonists on the behavioral response of rats to centrally administered corticotropin-releasing factor (CRF). Behavioral observations were done with animals in their home cages. Parameters measured included locomotor activity, grooming and food consumption. CRF alone increased locomotor activity. 8-OH-DPAT also increased locomotion in both saline control and CRF-treated rats. Buspirone had no effect on basal locomotion or on CRF-induced hyperactivity. Both buspirone and 8-OH-DPAT antagonized CRF-induced grooming. Food consumption by fasted rats was suppressed by ICV CRF. 8-OH-DPAT suppressed eating by both ICV CRF and ICV saline-treated animals, while buspirone was without effect. These results demonstrate differences between the two putative 5-HT-1A agonists in their effects on CRF-induced behaviour but also demonstrate that both suppress CRF-induced grooming.

Stimulation of the hypothalamic paraventricular nucleus produces analgesia not mediated by vasopressin or endogenous opioids

The analgesic effect of electrical stimulation of the hypothalamic paraventricular nucleus (PVN) was studied. Additionally, the involvement of vasopressin and opioid peptides in this process was examined by comparing vasopressin-deficient (Brattleboro) and Long-Evans rats and by administering the opiate antagonist naloxone. Rats were chronically implanted with a stimulating electrode in the parvocellular (PVN-Pc) and magnocellular (PVN-Mg) divisions of the PVN. At least 10 days after surgery, the analgesic effects of PVN stimulation were examined in lightly anesthetized rats, using the tail-flick method, and in unanesthetized rats, using the hot-plate test. PVN stimulation produced marked analgesia in both tests. Current threshold for analgesia was lower from PVN-Pc than from PVN-Mg. Threshold did not differ significantly between Brattleboro and Long-Evans rats and was not affected by naloxone administration. The results indicate that the PVN is part of the brain's pain inhibitory system, and show that the analgesia induced by PVN stimulation is not mediated by either vasopressin or opioid peptides.

The effects of rat corticotrophin-releasing factor-41 Peptide fragments on bioassay and immunoassay determination of corticotrophin-releasing factor-41 levels

Abstract Peptide fragments of rat corticotrophin-releasing factor-41 (CRF-41) containing amino-acid residues 21-33 antagonized the 5 nmol/l CRF-41-stimulated adrenocorticotrophin secretion from the adult rat pituitary gland in vitro. The CRF 6-33 sequence had antagonistic effects at equimolar (5 nmol/l) concentrations which were not observed at high (50 nmol/l) concentrations whilst the CRF 21-41 sequence had effects only at high (50 nmol/l) concentrations. Similar effects were observed with CRF 6-33 on basal release of adrenocorticotrophin. Peptide fragments elevated radioimmunoassay measurement of CRF-41 whilst inhibiting measurement of CRF-41 in a two-site enzyme amplified immunometric assay. The inhibitory effects of peptide fragments in the enzyme amplified immunometric assay could be removed by dilution to within the lower end of the standard curve or by increasing the concentration of antibody bound to the solid phase. These inhibitory effects mimic those of peptide fragments on basal adrenocorticotrophin release seen in a rat pituitary gland in vitro bioassay indicating that such two-site immunoassay determinations bear closer relation to bioactivity than those obtained using radioimmunoassay.

Effects of cortisol treatment on brain and adrenal corticotropin-releasing hormone (CRH) content and other parameters regulated by CRH

Corticotropin-releasing hormone (CRH) has been found in both hypothalamic and extrahypothalamic sites of the brain and also in the adrenal medulla. To study the timing and location of delayed glucocorticoid action in rats, we measured the effects of 2-day and 7-day cortisol treatment on immunoreactive CRH concentrations in hypothalamus, cerebral cortex, hippocampus, cerebellum, and adrenal gland. The activity of the hypothalamo-pituitary-adrenal (HPA) axis and the sympathoadrenal system were also measured. Studies were carried out both in the afternoon and/or in the morning, to get information about possible circadian changes. CRH contents were not changed in any brain areas studied, except there was a trend of decrease in the hypothalamus compared to vehicle in the afternoon due to the lack of circadian increase after 7-day cortisol treatment. Pituitary ACTH content decreased significantly after 7-day treatment, while beta-endorphin did not. Plasma levels of ACTH, corticosterone, norepinephrine and epinephrine and adrenal ACTH and beta-endorphin contents decreased after 2-day, adrenal CRH content after 7-day treatment with cortisol. Our findings suggest, that chronic cortisol treatment inhibits the circadian activation of the HPA axis at all levels but has variable effects on baseline measures because it causes different changes in release and synthesis at different sites.

CRF-like effects of sauvagine and urotensin I on synaptosomal tyrosine hydroxylase activity of mouse striatum

In the present study we have investigated whether sauvagine (SVG) and urotensin I (UT), two peptides displaying sequence homology with corticotropin-releasing factor (CRF), could affect synaptosomal tyrosine hydroxylase (TH) activity of mouse striatum in a manner similar to CRF. The enzyme activity was assayed in supernatants obtained following sonication and centrifugation of homogenates preincubated with the peptides. SVG and UT produced a concentration-dependent increase of TH activity with a half-maximal effect obtained at 5 and 10 nM, respectively. SVG and UT were as effective as CRF with maximal stimulations corresponding to 52-58% increase of basal enzyme activity, whereas the rank order of potency was SVG greater than UT = CRF. Kinetic analysis of TH activity versus low concentrations of the pterin co-factor (0.05-0.4 mM) indicated that the stimulations elicited by CRF, SVG and UT were associated with an increase in the Vmax of the enzyme form with high affinity for the co-factor. The CRF receptor antagonist alpha-helical CRF9-41 inhibited the effects of all 3 peptides. Moreover, the combined addition of CRF with either SVG or UT did not produce additive effects on TH activity. The stimulatory effects of CRF, SVG and UT were dependent on the concentration of extracellular free Ca2+, being minimal in a Ca2(+)-free medium and maximal at about 0.5 mM extracellular free Ca2+. These results indicate that SVG and UT can mimic the effect of CRF on synaptosomal TH by acting on a common receptor site associated with a Ca2(+)-dependent mechanism.

Effects of corticotropin-releasing factor on central respiratory activity

Effects of corticotropin-releasing factor (CRF) on central regulation of respiration were studied in urethane-anaesthetized, vagotomized, paralyzed and artificially ventilated rabbits. Injections of CRF into the IVth cerebral ventrile (i.c.v.) resulted in an increase of the neuronal tidal volume (nVt), but had only minor effects on the duration of respiratory phases. Microinjection of CRF into the ventral parabrachial region of the pons (pneumotaxic center) resulted in a reduction of nVt and of the respiration rate. Respiratory effects of CRF administered i.c.v. or into the pontine parabrachial region were antagonized by alpha-helical-CRF, indicating a receptor-mediated action of CRF. Respiratory effects of CRF were not significantly affected after blocking ganglionic transmission with chlorisondamine. Neither mean arterial blood pressure nor heart rate were significantly affected by the injection of CRF into the IVth ventricle or the rostral pons. Results suggest an involvement of CRF in the central regulation of respiratory movements. CRF may be involved in the adaptation of respiration to stress.

Presence of corticotropin-releasing factor-stimulated adenylate cyclase activity in rat retina

Corticotropin-releasing factor (CRF) stimulates rat retinal adenylate cyclase activity in a concentration-dependent manner. The half-maximal effect is obtained at 50 nM CRF and the maximal stimulation corresponds to approximately 90% increase of basal enzyme activity. The CRF effect is counteracted by the CRF antagonist alpha-helical CRF 9-41 with a Ki value of 40 nM. Other CRF-like peptides such as sauvagine and urotensin I are as effective as CRF with a rank order of potency of urotensin I greater than or equal to sauvagine greater than CRF. The sauvagine and urotensin I effects are not additive with that elicited by CRF. Moreover, the CRF stimulation is not additive with the increase of enzyme activity produced by vasoactive intestinal peptide or dopamine. The CRF effect is independent of the concentration of free Ca2+, is optimal at 5-10 mM MgCl2, and requires GTP. The results indicate that rat retinal adenylate cyclase is modulated by CRF via a receptor-mediated mechanism.

The anorectic effects of CRH and restraint stress decrease with repeated exposures

Intracerebroventricular (icv) administration of corticotropin-releasing hormone (CRH) or exposure to a restraint stressor causes acute anorexia in rats. However, the effects on food intake of repeated injections of CRH or repeated exposures to restraint stress have not been previously reported. As the effects of these more chronic CRH and stress treatments may be of greater relevance to emerging hypotheses of the pathogenesis of human eating and affective disorders, we measured the changes in food intake and body weight of rats after repeated central injections of CRH. In two experiments using two different daily dosages of CRH and two different schedules of administration, we found that the anorectic effect of CRH decreased over repeated injections. Weight gain was slowed significantly only in the high-dose experiment. Rats may become tolerant to the anorectic effects of CRH delivered by repeated icv injections. These findings have important implications for hypothesized mechanisms of anorexia nervosa and/or depression.

Corticotropin-releasing factor (CRF) increases paradoxical sleep (PS) rebound in PS-deprived rats

The intracerebroventricular injection (1 microgram) of murine corticotropin-releasing factor (r-CRF) to rats after 72 h of sleep deprivation markedly postponed the sleep onset, reduced slow wave sleep and prolonged the duration of paradoxical sleep (PS) episodes. Moreover, CRF is-to our knowledge-the first compound to be able to further prolong PS in a condition (sleep deprivation) in which its duration is already increased. Our findings raise the possibility that CRF might play a physiological role in the regulation of the sleep-wakefulness cycle.

Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: behavioral studies with pigeons

A number of studies have shown significant interactions between neuronal systems involved with corticotropin-releasing factor (CRF) and either the clinical manifestations of depression and anxiety or the effects of antidepressant or anxiolytic drugs. In the present study, effects of CRF were studied alone and in combination with imipramine and with the sedative-hypnotic/anxiolytic drugs pentobarbital and chlordiazepoxide. Interactions of CRF with the novel, atypical anxiolytic buspirone were also examined. Interactions were evaluated through the use of schedule-controlled responding, responding suppressed by punishment, and drug discrimination procedures using the conditioned key-pecking response of pigeons. Effects of CRF were significantly enhanced when given in combination with imipramine with low noneffective imipramine doses potentiating the rate-reducing effects of CRF. Similarly, in pigeons trained to discriminate imipramine from saline, noneffective doses of CRF shifted the imipramine dose-response curve more than twofold to the left. Low doses of imipramine that produced saline key responding, produced imipramine-key responding when coadministered with CRF. The CRF antagonist alpha-helical CRF9-41 did not alter the rate-decreasing effects of imipramine. Effects of CRF on schedule-controlled responding were, however, antagonized by the administration of chlordiazepoxide and pentobarbital but not by buspirone, suggesting that CRF interacts with the GABA/benzodiazepine receptor mechanism complex but not with those systems involved in mediating the effects of buspirone. These results suggest that CRF interacts in significant ways with specific neurotransmitter systems subserving depression and anxiety.

Gastrointestinal motor effects of corticotropin-releasing factor in mice

The present investigation examined the effects of centrally and peripherally administered corticotropin-releasing factor on gastric emptying and gastrointestinal transit in mice. Corticotropin-releasing factor, given either intracerebroventricularly or intrathecally, caused a dose-dependent inhibition of gastric emptyping and gastrointestinal transit. Intravenous or intraperitoneal administration of corticotropin-releasing factor, while 5- to 7-fold less potent than after central injection, produced an equivalent level of effect. alpha-Helical corticotropin-releasing factor, a corticotropin-releasing factor receptor antagonist, blocked the effects of intracerebroventricularly administered corticotropin-releasing factor when the antagonist was given concurrently by the intracerebroventricular, but not by the intraperitoneal, route. Conversely, corticotropin-releasing factor, when given peripherally, was antagonized equally well by intracerebroventricular or intraperitoneal administration of the antagonist. The inhibition of gastric emptying induced by corticotropin-releasing factor was reduced by pretreatment with the ganglionic blocking agent, chlorisondamine, and in adrenalectomized mice, but this effect was not antagonized by naloxone. These findings provide evidence for an action of corticotropin-releasing factor within the central nervous system, as well as a peripheral site of action, to inhibit gastric emptying in the mouse. The gastrointestinal motor effects of corticotropin-releasing factor are not mediated through opioid mechanisms although their full expression may require intact autonomic innervation and adrenal function.

Corticotropin-releasing factor receptors in the rabbit brain visualized by in vitro autoradiography

Corticotropin-releasing factor (CRF) binding sites were visualized in the rabbit brain by in vitro autoradiography using the radioligand 125I-[Tyr0]ovine CRF. The radioligand binding to sections of rabbit cingulate cortex were competed for by ovine and rat CRF with inhibitory constants (Ki) of 26 and 37 nM, respectively, whereas sauvagine and alpha-helical CRF9-41 were approximately 10-fold less potent. In the rabbit brain, the highest densities of binding sites for CRF are found in the pineal gland and the choroid plexus. The cerebral cortex is labelled throughout, with the highest concentration of binding sites in the piriform and primary olfactory divisions. In the cerebellar cortex, the granular layer is more intensely labelled than the molecular layer. The distribution of CRF binding sites in the hippocampus follows a laminar pattern; the molecular layer of the dentate gyrus is intensely labelled, the oriens, radiatum and lacunosum moleculare layers of Ammon's horn contain moderate densities of binding and no binding is observed in the granular layer of the dentate gyrus and the pyramidal cell layer. The ventral subnucleus of the lateral septum, the zonal and superficial layers of the superior colliculus contain high densities of receptors. A moderate concentration of binding sites is observed in the caudate nucleus, putamen, bed nucleus of the stria terminalis, paraventricular, anterodorsal and anteroventral thalamic nuclei and the medial nucleus of the mammillary body.(ABSTRACT TRUNCATED AT 250 WORDS)

Brain neuropeptide Y in the control of adrenocorticotropic hormone secretion in the dog

An immunoneutralization technique with specific antibodies was used to explore the role of endogenous neuropeptide Y (NPY) in the adrenocorticotropic hormone (ACTH) release after hypoglycemic stress in the dog. Dogs received injections of rabbit antihuman NPY gamma-globulin (anti-NPY) or normal gamma-globulin (NGG) into the third cerebral ventricle, which was followed by i.v. injection of insulin. Hypoglycemia of a 40% fall in systemic glucose levels occurred in anti-NPY-treated dogs as well as NGG-treated animals. An intraventricular administration of anti-NPY significantly inhibited the ACTH and cortisol release to hypoglycemia, but had no effect on the pancreatic polypeptide (PP) response. These findings suggest involvement by endogenous NPY in the ACTH secretion induced by hypoglycemia.

Decreased inflammatory responsiveness of hypophysectomized rats to heat is reversed by a corticotropin-releasing factor (CRF) antagonist

Hypophysectomy, but not adrenalectomy, decreased (relative to sham-operated controls) the swelling and Evans blue dye extravasation responses of the anesthetized rat's pawskin to thermal injury. alpha-Helical CRF (9-41), a synthetic competitive antagonist of corticotropin-releasing factor (CRF) on isolated pituitary cells, did not affect in sham-operated rats the swelling response after immersion of the paw in 58 degrees C water for 30 s. Swelling was measured over a 1 h period using the fluid displacement method for quantifying paw volume. But, when alpha-helical CRF (9-41) was injected 92 micrograms/kg i.v. 10 min before or immediately after heat exposure, it both attenuated and reversed the insensitive state produced by hypophysectomy: that is, the swelling response reappeared. Under the same test conditions, naloxone hydrochloride, an opioid antagonist, was ineffective. The results suggest that hypophysectomy may induce a condition whereby endogenous CRF or CRF-like peptides may act as an anti-inflammatory agent.

Fear-motivated behavior induced by prior shock experience is mediated by corticotropin-releasing hormone systems

In earlier studies, we established that in rats, antagonism of corticotropin-releasing hormone (CRH) receptors reduced the occurrence of fear-motivated behavior displayed immediately after administration of electric foot shock. Because exposure to stress is reported to have long-term behavioral and physiological effects, we examined whether central administration of the synthetic CRH receptor antagonist, alpha-helical CRH(9-41), would also alter fear-motivated behavioral and hormonal responses occurring 24 h after exposure to electric foot shock. Adult male rats were placed in a shock box and administered three, 1.0 mA foot shocks. Twenty-four hours later, rats received an intracerebroventricular infusion of 20 micrograms of alpha-helical CRH(9-41) or vehicle 20 min before re-exposure to the shock box. Antagonism of CRH receptors produced a significant reduction in fear-motivated freezing. However, stress-induced analgesia and plasma adrenocorticotropin concentrations did not differ significantly from vehicle-treated animals. In order to assess whether the reduction in freezing was due to intrinsic actions of the CRH receptor antagonist, non-shocked rats received central infusions of alpha-helical CRH(9-41) prior to re-exposure to the test box. Under these conditions, behavior exhibited by antagonist- and vehicle-treated rats did not differ significantly. Results suggest that the reduction in fear-motivated behavior is mediated by antagonism of endogenous CRH receptors and occurs independently of analgesic and hormonal reactions induced by prior exposure to stress.

The effects of corticotrophin-releasing factor and two antagonists on breathing movements in fetal sheep

1. The respiratory effects of corticotrophin-releasing factor (CRF) and the CRF antagonists alpha-helical CRF 9-41 (alpha hCRF) and [DPhe 12, Nle 21-38] rCRF (12-41) (DPhe CRF) have been studied in unanaesthetized fetal lambs of 125-140 days gestation. 2. CRF when given as a 10 micrograms bolus followed by a 5 micrograms h-1 infusion into a lateral cerebral ventricle caused prolonged continuous fetal breathing movements which were stimulated in both amplitude and frequency but which did not persist during hypoxia. 3. Lower doses of CRF (20 ng bolus followed by 10 ng h-1) increased the amplitude but not the frequency of fetal breathing movements which did not become continuous. 4. At higher doses (20 micrograms bolus followed by 10-15 micrograms h-1) CRF induced cerebral convulsions which were also associated with fetal breathing movements of increased amplitude and frequency. 5. The CRF antagonists alpha hCRF and DPhe CRF both inhibited fetal breathing movements and induced a prolonged apnoea which was resistant to the stimulatory effects of 5-6% hypercapnia. 6. We conclude that CRF stimulates breathing movements in the fetal lamb. The finding that administration of the CRF antagonists alone cause apnoea suggests that CRF may have a tonic role in the regulation of fetal breathing movements.

Convulsant peptides related to corticotropin-releasing factor (CRF)

Corticotropin-releasing factor (CRF) and its related peptides have some conserved primary regions. We have taken an interest in the characteristic conserved sequence, Pro-Pro-Ile-Ser, which is located in the proximal N-terminal region of the CRF family. This sequence is not included in any other biologically active peptide and protein. Biological function of this N-terminal region has not become known yet. We synthesized seventeen peptide fragments of human CRF and sauvagine which involved either this entire N-terminal sequence or part of it and determined their behavioural effect after intracerebroventricular injections to mice. Several peptides which included the Pro-Pro-Ile region as the N-terminal segment and their caused a transient convulsion dose-dependently. H-Pro-Pro-Ile-OH (human CRF(4-6)) exhibited the strongest effect among these active peptides. However, these convulsant peptides did not affect the secretion of immunoreactive corticotropin in rats.

Corticotropin-releasing factor inhibits the response of trigeminal neurons to noxious heat

In a previous study we reported that human/rat corticotropin-releasing factor (CRF) displayed antinociceptive activity in the mouse abdominal constriction assay. In this investigation we examined the effects of CRF on the evoked response of wide dynamic range (WDR) trigeminal neurons to noxious heat. Single units were recorded from the spinal trigeminal nucleus of urethane anesthetized rats. CRF inhibited the evoked response of these units in a dose-dependent manner with an ED50 of 2.3-7 nmol/kg i.v. Neither naloxone nor chlorisondamine pretreatment prevented the inhibitory actions of CRF. CRF-induced inhibition was also present in adrenalectomized and hypophysectomized animals. Intracerebroventricular administration of CRF did not inhibit the heat evoked response of WDR trigeminal units. alpha-Helical CRF, a CRF receptor antagonist, 12 nmol/kg i.v., alone did not affect the response of trigeminal units to heat, but pretreatment of animals with this dose blocked the inhibitory actions of CRF. By contrast to the inhibitory effects of CRF on heat-responsive units, CRF, 6-18 nmol/kg i.v., increased the spontaneous discharge rate of cold-responsive units by 57 +/- 16%. The data show that CRF selectively inhibits neuronal responses to noxious heat, an action that is independent of the pituitary-adrenal axis. These results are viewed as further evidence that CRF has antinociceptive properties in the periphery.

CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice

Corticotropin-releasing factor (CRF) and restraint-stress both decrease exploratory behavior in rats and mice. The involvement of pituitary-adrenal hormones in eliciting these behavioral effects was examined using hypophysectomized mice. Forty minutes of restraint decreased exploratory behavior in hypophysectomized mice just as it did in intact animals. Similarly, CRF (50 ng) injected into the lateral cerebral ventricles of hypophysectomized mice decreased exploratory behavior. Therefore, the restraint- and CRF-induced decreases of exploratory behavior are apparently independent of the activation of ACTH secretion from the pituitary. It seems likely that CRF acts intracerebrally to elicit this effect of restraint, especially because a CRF antagonist can reverse the effects of restraint.

Peptides of the corticoliberin superfamily attenuate thermal and neurogenic inflammation in rat pawskin

The paws of pentobarbital-anesthetized rats were immersed in 48 or 58 degree C water for 5 min and the thermal inflammatory response to heat was measured by Evans blue dye leakage into the pawskin. Sauvagine, sucker fish urotensin I and human/rat corticotropin-releasing factor (CRF), homologous peptides belonging to the corticoliberin superfamily, injected i.v. 10 min before heat exposure, inhibited dye leakage with ED50 (nmol/kg) of 0.44, 1.5 and 5.9, respectively. The same rank order of potency was observed when the peptides were tested against the protein extravasation evoked by antidromic stimulation of the rat saphenous nerve. The alpha-helical CRF-(-9-41) antagonist, administered alone at 24 nmol/kg i.v., did not affect the heat-induced dye leakage into skin; but it attenuated the effects of h/rCRF, urotensin I and sauvagine. h/r[Tyr0]CRF, ovine[Nle21,Tyr32]CRF and h/r[Met(O)21,38]CRF, administered 24 nmol/kg i.v., did not affect the dye leakage response to heat. Peptides of the corticoliberin superfamily may have the unusual property of making small blood vessels less permeable when responding to injurious stimuli.

Stimulation of synaptosomal dopamine synthesis by corticotropin-releasing factor in rat striatum: role of Ca2+-dependent mechanisms

Corticotropin-releasing factor (CRF) stimulated synaptosomal dopamine (DA) synthesis in rat striatal homogenates. The stimulatory effect of CRF was antagonized by alpha-helical CRF 9-41 and was dependent on the extracellular Ca2+ concentration, being absent after removal of Ca2+ from the incubation medium and maximal at about 1.2 mM extracellular Ca2+. The stimulation of DA synthesis by forskolin (FSK) was less sensitive to a change of extracellular Ca2+ concentration. 3-Isobutyl-1-methylxanthine potentiated the FSK effect but did not affect the response to CRF. CRF stimulation was additive to that produced by 40 mM KCl and was little affected by the calmodulin inhibitor, W-7, which markedly suppressed the veratridine-induced stimulation of DA synthesis. Polymyxin B antagonized the CRF stimulation while it had a weaker effect on FSK-stimulated DA synthesis. Tolbutamide reduced the FSK stimulation more effectively than the CRF response. CRF elicited a non-significant increase of cyclic AMP formation by striatal membranes. These results indicate that CRF stimulates striatal DA synthesis by a Ca2+-dependent mechanism possibly involving the activation of the protein kinase C pathway.

Stimulation of rat B-lymphocyte proliferation by corticotropin-releasing factor

The mitogenic effect of corticotropin-releasing factor (CRF) on rat lymphocytes was investigated. When rat splenocytes were cultured for 48 hr with CFR, a dose-dependent increase in incorporation of 3H-thymidine (3H-Tdr) was observed, with a maximal response at 10 nM CRF. Comparison of the proliferative effect of CRF on enriched populations of B lymphocytes, T lymphocytes, or macrophages revealed that only B lymphocytes responded following treatment with CRF. When lymphocytes derived from different lymphoid tissues were compared, CRF had a greater proliferative effect on lymphocytes derived from gut-associated lymphoid tissue (mesenteric lymph nodes and Peyer's patches) than on lymphocytes from spleen or inguinal lymph nodes; CRF had no effect on thymocytes. Synthetic fragments of CRF were used to determine which portions of the peptide are recognized by lymphocytes. The C-terminal fragments alpha-helical CRF9-41 and CRF21-41 were as potent as native CRF in stimulating B-lymphocyte proliferation, whereas CRF1-20 did not stimulate proliferation. The activity of these peptides suggests that CRF stimulates lymphocyte proliferation by cellular recognition of structural determinants in the C-terminal one-half of the peptide.

Corticotropin-releasing factor stimulates the release of methionine-enkephalin and dynorphin from the neostriatum and globus pallidus of the rat: in vitro and in vivo studies

This study examined the changes in the in vitro and in vivo release of methionine-enkephalin (Met-enkephalin), and dynorphin from the rat neostriatum in response to corticotropin-releasing factor (CRF). The levels of each opioid peptide were measured in the same sample collected at each time interval by specific radioimmunoassay methods. The in vitro release experiments were conducted using neostriatal slices (250 microns) obtained from adult male Wistar rats whereas in the in vivo studies, the release of both Met-enkephalin and dynorphin were assessed in push-pull perfusates of the caudate nucleus (containing both Met-enkephalin and dynorphin cell bodies/fibres) and the globus pallidus (containing Met-enkephalin and dynorphin terminals) of chloral hydrate-anaesthetised adult male Wistar rats. In the in vitro studies, CRF (10(-12), 10(-10) and 10(-8) M) (applied in pulses of 75 min) stimulated both Met-enkephalin and dynorphin release from the neostriatal slices in a dose-related manner; in the presence of the CRF receptor antagonist, alpha-helical CRF9-41 (10(-6) M) the release of both Met-enkephalin and dynorphin in response to CRF (10(-8) M) were completely blocked. Push-pull perfusion experiments conducted in both the caudate nucleus and the globus pallidus, also demonstrated a dose-related increase in the release of both Met-enkephalin and dynorphin in response to CRF (10(-12), 10(-10) and 10(-8) M) applied in 60-min pulses. In addition, in each of the two brain sites, the release of both Met-enkephalin and dynorphin in response to CRF (10(-8) M) was completely blocked by alpha-helical CRF9-41 (10(-6) M). Both the in vitro and in vivo studies thus demonstrate that CRF can exert potent effects on Met-enkephalin and dynorphin release within the neostriatum-pallidum of the rat and that such effects are mediated via receptors specific for CRF, probably located on both the cell bodies and terminals of these opioid-containing neurones. The data obtained in this study thus substantiate the view that CRF, in addition to its regulation of pituitary opioid peptides, can communicate to opioid-containing neurones within the central nervous system and that many of the effects elicited by CRF may be ascribed to the opioid peptide released by CRF.(ABSTRACT TRUNCATED AT 400 WORDS)

Stimulation of GABA release from the rat neostriatum and globus pallidus in vivo by corticotropin-releasing factor

This study conducted in vivo examined the changes in gamma-aminobutyric acid (GABA) release in push-pull perfusates of the caudate nucleus (CN) and the globus pallidus (GP) in response to corticotropin releasing factor (CRF). In the CN, CRF (10(-12), 10(-10), 10(-8) M) stimulated GABA release in a dose-related manner, the highest dose (10(-8) M) also potentiating the 25 mM K+-evoked response. The release of GABA in response to CRF (10(-8) M) was completely blocked by alpha-helical CRF9-41 (10(-6) M) which also attenuated the K+-evoked response to control K+-stimulated levels. In the GP, only the highest dose of CRF (10(-8) M) significantly stimulated GABA release, this dose also potentiating the K+-evoked release. Both responses were attenuated by the CRF receptor antagonist (10(-6) M). These results thus demonstrate that CRF can exert potent effects on GABA release within the rat neostriatum-pallidum by increasing the membrane excitability of GABA neurons/terminals and that such effects are mediated via receptors present on both the cell bodies/terminals of GABA-containing neurones. These effects of CRF suggest that the peptide may be an integral component of the neurochemical circuitry in the basal ganglia with relevance to the regulation of motor behaviour.

Corticotrophin-Releasing Factor Antagonist [alpha helical CRF(9-41)] Blocks Central Noradrenaline-lnduced ACTH Secretion

Plasma ACTH increased after an intra-third ventricular administration of noradrenaline (NA). An iv corticotrophin-releasing factor (CRF) antagonist [alpha-helical CRF(9-41)] injection did not affect ACTH secretion by itself, whereas it significantly reduced NA-induced ACTH secretion. These results suggest that NA centrally stimulated ACTH secretion and that endogenous CRF is involved in this ACTH secretion.

CRH and alpha-helical-CRH modulate behavioral measures of arousal in monkeys

Several neuropeptides involved in the control of pituitary-adrenal activation have also been shown to have behavioral effects which may be mediated by actions on brain mechanisms independent of pituitary release. The behavioral effects of intraventricular administration of CRH and the synthetic peptide antagonist alpha-helical-CRH were assessed in socially separated squirrel monkeys. Treated monkeys were presented with a sequence of behavioral challenges including undisturbed social separation, presentation of a mirror image, and presentation of a "predator" stimulus. The test sequence was repeated at several time intervals after administration of the peptides. CRH produced dose-related increases in several species-typical measures of arousal including motor activity, vigilance-checking, and marking. Pretreatment with alpha-helical-CRH prevented the increased motor activity but not the marking behavior associated with CRH. When administered alone, alpha-helical-CRH increased vigilance-checking. In addition, alpha-helical-CRH increased aggressive behaviors exhibited at the mirror stimulus. The data provide further support for a central role for CRH in the mediation of both activational and inhibitory behavioral responses to stressful stimuli. These data also suggest both antagonistic and partial agonist effects for alpha-helical-CRH.

Functional corticotropin-releasing factor (CRF) receptors in mouse spleen: evidence from adenylate cyclase studies

Radioligand binding studies have previously identified a high affinity, magnesium-dependent, guanine nucleotide-sensitive binding site for corticotropin-releasing factor (CRF) in mouse spleen. In order to determine the functional nature of these CRF binding sites, we examined the effects of CRF on adenylate cyclase activity in mouse spleen homogenates. The stimulation of adenylate cyclase activity was dependent on time, tissue protein concentration, and guanine nucleotides. CRF-stimulated adenylate cyclase activity was evident in the presence of guanosine-5'-triphosphate (GTP) and its precursor guanosine-5'-diphosphate (GDP) but was not detected in the presence of the hydrolysis-resistant GTP analogs, guanyl-5'-imidodiphosphate [Gpp(NH)p] and guanosine-5'-gamma-thiotriphosphate (GTP-gamma-S). The rank order of potency for CRF analogs and fragments in stimulating adenylate cyclase activity was comparable to their affinities for CRF binding sites in mouse spleen homogenates. The putative receptor antagonist, alpha helical ovine CRF(9-41), did not stimulate adenylate cyclase activity but did attenuate the stimulation by various concentrations of rat/human CRF. In summary, these data demonstrate the functional nature of CRF receptors in mouse spleen as evidenced by CRF stimulation of cAMP production and suggest that this peptide may play a physiological role in regulating immune function.

Regulation of duodenal bicarbonate secretion during stress by corticotropin-releasing factor and beta-endorphin

Proximal duodenal mucosal bicarbonate secretion is an important factor in the pathogenesis of duodenal ulcer disease. To examine the central nervous system regulation of duodenal bicarbonate secretion, an animal model was developed that allowed cerebroventricular and intravenous injections as well as collection of duodenal perfusates in awake, freely moving rats. The hypothalamic peptide corticotropin-releasing factor (CRF) and stress (physical restraint) significantly stimulated duodenal bicarbonate secretion. These responses were abolished by pretreatment of the animals with the CRF receptor antagonist alpha-helical CRF-(9-41), hypophysectomy, and naloxone. In contrast, blockade of autonomic efferents by surgical and pharmacological means did not prevent the stimulatory effects of stress and CRF. Intravenous, but not cerebroventricular, administration of beta-endorphin that produced plasma concentrations of beta-endorphin that were similar to those produced by exogenous CRF and stress significantly stimulated duodenal bicarbonate secretion. These results indicate that endogenous CRF released during stress and exogenously administered CRF stimulate duodenal bicarbonate secretion by release of beta-endorphin from the pituitary, thus, demonstrating a functional hypothalamus-pituitary-gut axis.

Effect of neuropeptide Y on the hypothalamic-pituitary-adrenal axis in the dog

There is increasing evidence that neuropeptide Y (NPY) affects the release of pituitary hormones, including adrenocorticotropic hormone (ACTH). The present study was designed to clarify the mechanism by which NPY activates the hypothalamic-pituitary-adrenal (HPA) axis in the dog. Mongrel dogs were equipped with a chronic cannula allowing intra-third (i.t.v.) or intra-lateral (i.l.v.) cerebroventricular administration. A 1.19 nmol, i.t.v. dose of NPY produced as great an ACTH and cortisol response as did equimolar ovine corticotropin releasing factor (CRF). This action of NPY was dose-dependent and shared by peptide YY (PYY) and pancreatic polypeptide (PP), other members of the PP family peptide. Intravenously (i.v.) administered NPY (1.19-11.9 nmol) was much less potent than i.v. CRF in stimulating ACTH and cortisol secretion. However, i.v. NPY significantly increased plasma ACTH and cortisol concentrations, raising the possibility that NPY may modulate the activity of corticotrophs. We have next investigated the possible relationship between NPY and CRF on the HPA axis. Pretreatment with a novel CRF antagonist, alpha-helical CRF9-41 (130.9 nmol i.t.v. or 261.8 nmol i.v.), partly but significantly attenuated the ACTH and cortisol responses to i.t.v. NPY (1.19 nmol). Furthermore, adding a subthreshold dose of i.t.v. NPY (0.119 nmol) to i.t.v. CRF (1.19 nmol) or i.v. NPY (2.38 nmol) to i.v. CRF (0.595 nmol) resulted in the potentiation of CRF-induced ACTH secretion. These results indicate that NPY may activate the HPA axis in concert with CRF probably at hypothalamic and/or pituitary levels. The present findings that NPY evokes ACTH secretion and potentiates the effectiveness of CRF as a secretagogue, together with high concentrations of NPY in the hypothalamus and pituitary portal blood, suggest that NPY is involved in the multihormonal control of ACTH release.

Central administration of corticotropin releasing factor alters rat pup isolation calls

Rat pups, when socially isolated, emit ultrasonic vocalizations which are believed to indicate distress. This study investigated the effect of intracerebroventricular (ICV) administration of corticotropin releasing factor (CRF) on the production of ultrasonic isolation calls. Following a 2-minute baseline isolation test, rat pups (5-6 days old) were injected ICV with CRF or the CRF antagonist, alpha-helical CRF (9-41). Thirty minutes later, calls were significantly decreased following CRF (0.1 and 0.01 micrograms) and increased following the CRF antagonist (1.0 micrograms). These effects were not explained by changes in locomotor activity, thermoregulation, or plasma glucocorticoid levels following peptide administration. Peripheral administration of CRF (1.0 and 10.0 micrograms) did not alter the number of isolation calls.

Immunocytochemical detection of corticotropin-releasing factor: multiple cross-reactions of a widely used carboxy-terminally directed corticotropin-releasing factor antiserum (code rC70) in rat hypothalamus

Forty-one-residue corticotropin-releasing factor is a physiologically significant mediator of the hypothalamic control of corticotropin secretion by the anterior pituitary gland. This releasing hormone is produced by parvicellular neurons in the hypothalamic paraventricular nucleus that project to the external zone of the median eminence. Recent immunocytochemical evidence based on work with a rabbit antiserum against rat corticotropin-releasing factor (code rC70) suggests that about half of the parvicellular corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus synthesize vasopressin, another potent corticotropin secretagogue, while the rest of the cells do not. If this is indeed the case, the neurohumoral control of corticotropin release may be mediated via distinct hypothalamic effector pathways utilizing releasing hormone cocktails of varying composition. In the present study we have examined the specificity of various antisera against rat corticotropin-releasing factor in immunocytochemical staining. Male Wistar rats pretreated with colchicine were used throughout. The brain was fixed by perfusion with a Zamboni type fixative solution. Vibratome sections of the hypothalamus were immunostained with three different primary antisera (codes rC70, rCRF-3, oCRF-N) using the peroxidase-antiperoxidase or avidin-biotin complex methods. All three antisera stained cell groups previously described to be immunopositive for corticotropin-releasing factor. Most notably, however, rC70 labelled a significant number of additional cells, most readily identified in the arcuate and suprachiasmatic nuclei, as well as in the dorsolateral hypothalamic area caudal to the paraventricular nucleus.(ABSTRACT TRUNCATED AT 250 WORDS)

Identification of peptide hormones of the amphipathic helix class using the helical hydrophobic moment algorithm

Eisenberg's helical hydrophobic moment (less than mu H greater than) algorithm was applied to the analysis of the primary structure of amphipathic alpha-helical peptide hormones and an optimal method for identifying other peptides of this class determined. We quantitate and compare known amphipathic helical peptide hormones with a second group of peptides with proven nonamphipathic properties and determine the best method of distinguishing between them. The respective means of the maximum 11 residue less than mu H greater than for the amphipathic helical and control peptides were 0.46 (+/-/-0.07) and 0.33 (0.07) (P + 0.004). To better reflect the amphipathic potential of the entire peptide, the percent of 11 residue segments in each peptide above a particular less than mu H greater than was plotted vs less than mu H greater than. The resulting curves are referred to as HM-C. The mean HM-C (of the two groups) was highly significantly different such that the HM-C method was superior to others in its ability to distinguish amphipathic from nonamphipathic peptides. Several potential new members of this structural class were identified using this approach. Molecular modeling of a portion of one of these, prolactin inhibitory factor, reveals a strongly amphipathic alpha helix at residues 4-21. This computer-based method may enable rapid identification of peptides of the amphipathic alpha-helix class.

Corticotropin-releasing factor and adrenocorticotropin stimulate ciliary motility in rabbit tracheal epithelium

To assess the effects of corticotropin-releasing factor (CRF) and adrenocorticotropin (ACTH) on airway ciliary activity, we measured ciliary beat frequency (CBF) by a photoelectric method in response to these peptides in cultured rabbit tracheal explants. When cumulatively added, both CRF and ACTH increased CBF in a dose-dependent fashion. Treatment of tissues with Ca2+-free medium or nifedipine abolished the effect of CRF but not of ACTH. The CRF- and ACTH-induced ciliostimulations were not affected by indomethacin or autonomic antagonists, but were attenuated by nordihydroguaiaretic acid and by their receptor antagonists, alpha-helical CRF (9-41) and ACTH (7-38). Intracellular cyclic AMP levels were significantly increased by CRF and ACTH. These results suggest that CRF and ACTH stimulate airway ciliary motility through the activation of adenylate cyclase and lipoxygenase by binding to their specific receptors, where the effect of CRF may be triggered by Ca2+ influx.

Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor

Corticotropin-releasing factor (CRF) has been implicated as a central nervous system mediator of stress. This study examined the effects of CRF and stress on gastric secretory and gastrointestinal motor functions in rats. Partial body restraint as a stress-producing stimulus significantly decreased gastric acid secretion, gastric emptying, and small bowel transit but markedly increased large bowel transit. Corticotropin-releasing factor given cerebroventricularly mimicked the gastrointestinal secretory and motor responses induced by partial body restraint. Cerebroventricular administration of a specific CRF receptor antagonist, alpha-helical CRF-(9-41), but not of the CRF fragment CRF-(1-20), prevented the gastrointestinal secretory and motor responses elicited either by partial body restraint or by exogenous administration of CRF in a dose-dependent fashion. These results suggest that the gastrointestinal secretory and motor responses in rats produced by stress (partial body restraint) are mediated by the endogenous release of CRF. They also indicate that CRF exerts its central nervous system actions on the gastrointestinal tract by a receptor-mediated event.